Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (17163)	6/6/2003 1:04:56 PM
From: sjemmeri	Read Replies (1) \| Respond to of 78516

I recall (as you may also) posting a list of what I thought were then cheap biotechs (some below cash) that I bought last year. Well, they all got cheaper. And I added shares and bought other ones and ended up with a very outsized position (but well diversified within the group) that was just killing me until the tide turned this spring. Recently, I've pared that overall position way back (sold all of some of them and some of all of them) and ended up doing fine. But it's been a wild ride. The ones I still own I haven't looked at the price relative to cash lately as I eventually started watching for milestones, and presentations, and deals with big pharma, and results of Phase I/II/II trials, and FDA decisions, etc.

To: Paul Senior who wrote (17163)	6/6/2003 5:13:24 PM
From: Steve168	Respond to of 78516

Paul, I agree there have been many buyers on those under-cash plays and the trend is continuing. I belive under current positive atmosphere in stock market (boy the RUT and NASDAQ are on drugs), those stocks should reach cash value in the next month or two. The market will take a breath here and there, but a 10-20% rise from here is almost certain to me. I could be wrong but I am betting on it, like I bet on buying ALVR @1.86 and VICL/PCYC under 4.